Sprouts Farmers Market closes $600 million revolving credit facility
Michael E. Prevoznik, Senior Vice President and General Counsel at Quest Diagnostics Inc. (NYSE:DGX), has sold a portion of his holdings in the company. According to a recent SEC filing, Prevoznik sold 4,643 shares of common stock at a price of $170 per share, totaling approximately $789,310. Following this transaction, Prevoznik holds 38,117 shares directly. The sale comes as Quest Diagnostics, a prominent player in the Healthcare Providers & Services industry with a market capitalization of $18.7 billion, trades near its 52-week high. InvestingPro analysis indicates the stock is currently trading above its Fair Value.
This sale was conducted under a Rule 10b5-1 sales plan, which allows company insiders to sell a predetermined number of shares at a predetermined time. Additionally, Prevoznik indirectly owns 5,641 shares through the company’s tax-qualified Profit Sharing (401(k)) and Supplemental Deferred Compensation Plan. The company maintains strong fundamentals with an "GOOD" Financial Health score and has raised its dividend for 13 consecutive years. Want deeper insights into insider trading patterns and comprehensive analysis? Access Quest Diagnostics’ full Pro Research Report, along with 1,400+ other detailed company analyses, on InvestingPro.
In other recent news, Quest Diagnostics has reported its financial outlook and strategic initiatives during its 2025 Investor Day. The company reaffirmed its full-year 2025 guidance with projected net revenues between $10.70 billion and $10.85 billion and an adjusted diluted EPS ranging from $9.55 to $9.80. However, Quest anticipates a first-quarter revenue headwind of approximately $25 million and an EPS headwind of about $0.10 due to adverse weather conditions. In a strategic move, Quest Diagnostics has partnered with Google (NASDAQ:GOOGL) Cloud to enhance data management and AI personalization, aiming to improve diagnostics and patient care.
Analysts have reacted to these developments with mixed responses. Citi downgraded Quest Diagnostics from Buy to Neutral, setting a price target of $185, citing concerns over margin pressures and earnings growth. Conversely, Baird maintains an outperform rating, expecting earnings acceleration in 2025. JPMorgan has raised its price target to $180, acknowledging the company’s solid clinical lab operations and strong year-over-year revenue growth. Quest Diagnostics continues to focus on strategic initiatives, including automation and AI, to drive future growth and productivity.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.